PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-7.40%
Negative ROE while Biotechnology median is -10.52%. Seth Klarman would investigate if capital structure or industry issues are at play.
-6.83%
Negative ROA while Biotechnology median is -9.08%. Seth Klarman would consider if assets are underutilized or if it’s a distressed opportunity.
-7.50%
Negative ROCE while Biotechnology median is -9.85%. Seth Klarman would investigate whether a turnaround is viable.
85.43%
Gross margin of 85.43% while Biotechnology median is zero. Walter Schloss would see if minimal margin can be scaled up.
-549.36%
Negative operating margin while Biotechnology median is 0.00%. Seth Klarman would look for a path to operational turnaround.
-541.91%
Negative net margin while Biotechnology median is 0.00%. Seth Klarman would see if cost cuts or revenue growth can fix losses.